<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:department>Contracts Office</gtr:department><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/74309877-4229-47B6-8199-A4CC49110A03"><gtr:id>74309877-4229-47B6-8199-A4CC49110A03</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Maxwell</gtr:surname><gtr:orcidId>0000-0002-5756-6430</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FJ%2F000CA436"><gtr:id>50ADD6C7-E6EF-435D-B2D6-3DDB5A019D7B</gtr:id><gtr:title>More Medicines for Tuberculosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/J/000CA436</gtr:grantReference><gtr:abstractText>The More Medicines for Tuberculosis (MM4TB - EU FP7) consortium has evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), which delivered a candidate drug for clinical development. Building on these foundations, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. The role of JIC (AM lab) will be to develop M. tuberculosis gyrase as a target and establishing the mechanism of action of novel compounds that target this enzyme. This will involve biochemistry and structural methods (X-ray crystallography), carried out in collaboration with the Lawson laboratory. Medicinal chemistry, carried out in other labs in the consortium, will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.</gtr:abstractText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-02-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>203422</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The EU team have been exploring novel compounds as potential TB agents. Some of these compounds will be used to develop new TB drugs.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>648AB2C6-FB36-4B25-8444-38F3445B7539</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544d1974c78282.17377879</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have evaluated about 300,000 compounds for their potential as anti-TB compounds. Some of these will be considered as new TB drugs.</gtr:description><gtr:exploitationPathways>Others may pick up these findings and use the data in drug-development programmes</gtr:exploitationPathways><gtr:id>BCEE1F35-79F4-4E42-9223-7D5DF9997A8A</gtr:id><gtr:outcomeId>544d1a19c318e3.86437829</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.mm4tb.org/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E0309196-1266-40ED-8A3C-798711E7AC02</gtr:id><gtr:title>DNA topoisomerase I and DNA gyrase as targets for TB therapy.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abd06e5a1cc32d6d81c64037bf43b97c"><gtr:id>abd06e5a1cc32d6d81c64037bf43b97c</gtr:id><gtr:otherNames>Nagaraja V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>58c2bd70de81e4.24228515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADDB8A66-1BC2-44F0-92A1-991A6C504401</gtr:id><gtr:title>Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f95d999f95b5f60a10628a1e9126a1e"><gtr:id>4f95d999f95b5f60a10628a1e9126a1e</gtr:id><gtr:otherNames>Djaout K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c2be57981db4.36587644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A82989B-A51F-4E47-8783-A0A9B5C8B788</gtr:id><gtr:title>Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b2ba50abeae1db81721000e04832aa4"><gtr:id>9b2ba50abeae1db81721000e04832aa4</gtr:id><gtr:otherNames>Sipos A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>56c2091066a3c1.96030230</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/J/000CA436</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>